IRWD Ironwood Pharmaceuticals Inc.

12.48
+0.15  (+1%)
Previous Close 12.33
Open 12.44
Price To Book -12.73
Market Cap 1,957,090,212
Shares 156,818,126
Volume 1,534,121
Short Ratio
Av. Daily Volume 1,463,125
Stock charts supplied by TradingView

NewsSee all news

  1. Dermira Elects Halley E. Gilbert to its Board of Directors

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  2. Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the 28th Annual Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 4:10 p.m. Mountain Standard Time (6:10 p.m. Eastern

  3. Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance

    – Total revenue of $131 million, driven primarily by LINZESS® (linaclotide) U.S. collaboration revenue of $85 million and ex-U.S. license and milestone revenue of $42 million – – $21 million in GAAP net income from

  4. Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

    – Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent – – AstraZeneca obtains

  5. Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present corporate updates at two upcoming investor conferences in September: 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 2:25 p.m. ET at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced August 21, 2017.
DUZALLO (LESINURAD AND ALLOPURINOL)
Hyperuricemia associated with gout
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 3b data met all endpoints - June 18, 2019.
Linaclotide
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
IW-9179
Gastroparesis
Phase 3 data due 2H 2020.
IW-3718
Gastroesophageal reflux disease (GERD)
No additional trials planned.
IW-1701
Achalasia
Phase 2 top-line data due mid-2020.
MD-7246
Irritable Bowel Syndrome

Latest News

  1. Dermira Elects Halley E. Gilbert to its Board of Directors

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  2. Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the 28th Annual Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 4:10 p.m. Mountain Standard Time (6:10 p.m. Eastern

  3. Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance

    – Total revenue of $131 million, driven primarily by LINZESS® (linaclotide) U.S. collaboration revenue of $85 million and ex-U.S. license and milestone revenue of $42 million – – $21 million in GAAP net income from

  4. Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

    – Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent – – AstraZeneca obtains

  5. Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present corporate updates at two upcoming investor conferences in September: 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 2:25 p.m. ET at